The chronic obstructive pulmonary disease-asthma overlap syndrome

Allergy and Asthma Proceedings

Volumn 36, Issue 1, 2015, Pages 11-18

  Braman, Sidney S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; IPRATROPIUM BROMIDE PLUS SALBUTAMOL;

AIRWAY OBSTRUCTION; ARTICLE; ASTHMA; ATOPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC OBSTRUCTIVE PULMONARY DISEASE ASTHMA OVERLAP SYNDROME; CLINICAL FEATURE; COST OF ILLNESS; EMPHYSEMA; EOSINOPHILIA; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEALTH CARE UTILIZATION; HUMAN; MORTALITY; PHENOTYPE; QUALITY OF LIFE; SMOKING; SPIROMETRY; WHEEZING; COMPLICATION; DIFFERENTIAL DIAGNOSIS; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SYNDROME;

ASTHMA; DIAGNOSIS, DIFFERENTIAL; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SYNDROME;

EID: 84919725829     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2015.36.3802     Document Type: Article

References (66)

1. Celli BR, and MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. Eur Respir J 23:932-46, 2004.
2. Anderson GP. Endotyping asthma: New insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 372: 1107-1119, 2008.
3. Beasley R, Weatherall M, Travers J, and Shirtcliffe P. Time to define the disorders of the syndrome of COPD. Lancet 374:670-672, 2009.
4. Travers J, Weatherall M, Fingleton J, and Beasley R. Towards individualised medicine for airways disease: Identifying clinical phenotype groups. Eur Respir J 39:1033-1044, 2012.
5. Mannino DM. COPD: Epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 121(suppl 5): 121S-126S, 2002.
6. Orie NG. The Dutch hypothesis. Chest 117(suppl):299S, 2000.
7. National Asthma Education and Prevention Program. Third expert panel on the diagnosis and management of asthma. Expert panel report 3: Guidelines for the diagnosis and management of asthma. NIH publication no. 07-4051, 2007.
8. Dodge R, Cline MG, and Burrows B. Comparisons of asthma, emphysema, and chronic bronchitis diagnoses in a general population sample. Am Rev Respir Dis 133:981-986, 1986.
9. Soriano JB, Davis KJ, Coleman B, et al. The proportional Venn diagram of obstructive lung disease. Two approximations from the United States and the United Kingdom. Chest 124:474-481, 2003.
10. Stoller JK, Smith P, Yang P, and Spray J. Physical and social impact of alpha-antitrypsin deficiency: Results of a survey. Cleve Clin J Med 61:461-467, 1994.
11. Pellegrino R, Viegi G, Brusasco V, et al. Standardization of lung function tests. Eur Respir J 26:948-68, 2005.
12. Kesten S, and Rebuck AS. Is the short-term response to inhaled beta-adrenergic agonist sensitive or specific for distinguishing between asthma and COPD? Chest 105:1042-1045, 1994.
13. Tashkin DP, Celli B, Decramer M, et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J 31:742-750, 2008.
14. Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 161:309-329, 2000.
15. Davis BE, and Cockcroft DW. Past, present and future uses of methacholine testing. Expert Rev Respir Med 6:321-329, 2012.
16. Tashkin DP, Altose MD, Connett JE, et al. Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. Am J Respir Crit Care Med 153:1802-1811, 1996.
17. Bourdin A, Serre I, Flamme H, et al. Can endobronchial biopsy analysis be recommended to discriminate between asthma and COPD in routine practice? Thorax 59:488-493, 2004.
18. Postma DS, Kerkhof M, Boezen HM, and Koppelmman GH. Asthma and chronic obstructive pulmonary disease: Common genes, common environments? Am J Respir Crit Care Med 183:1588-1594, 2011.
19. Moorman JE, Akinbami LJ, Bailey CM, et al. National surveillance of asthma: United States, 2001-2010. Vital Health Stat 3:1-67, 2012.
20. Ford ES, Croft JB, Mannino DK, et al. COPD surveillance-United States 1999-2011. Chest 144:283-305, 2013.
21. da Silva LF, Saldiva SR, Saldiva PH, and Dolhnikoff M. Bandeira Científica Project Impaired lung function in individuals chronically exposed to biomass combustion. Environ Res 112: 111-117, 2012.
22. Babalik A, Bakirci N, Taylan M, et al. Biomass smoke exposure as a serious health hazard for women. Tuberk Toraks 61:115-121, 2013.
23. Kurmi OP, Semple S, Simkhada P, et al. COPD and chronic bronchitis risk of indoor air pollution from solid fuel: A systematic review and meta-analysis. Thorax 65:221-228, 2010.
24. Gelb AF, and Zamel N. Unsuspected pseudophysiologic emphysema in chronic persistent asthma. Am J Respir Crit Care Med 162:1778-1782, 2000.
25. Schachter EN, Coyle CA, and Beck GJ. A prospective study of asthma in a rural community. Chest 85:623-630, 1984.
26. Peat JK, Woolcock AJ, and Cullen K. Rate of decline of lung function in subjects with asthma. Eur J Respir Dis 70:171-179, 1987.
27. Ulrik CS, and Lange P. Decline of lung function in adults with bronchial asthma. Am J Respir Crit Care Med 150: 629-634, 1994.
28. Lange P, Parner J, Vestbo J, et al. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 339: 1194-1200, 1998.
29. Brown PJ, Greville HW, and Finucane KE. Asthma and irreversible airflow obstruction. Thorax 39:131-136, 1984.
30. Braman SS, Kaemmerlen JT, and Davis SM. Asthma in the elderly. A comparison between patients with recently acquired and long-standing disease. Am Rev Respir Dis 143:336-340, 1991.
31. Reed CE. The natural history of asthma in adults: The problem of irreversibility. J Allergy Clin Immunol 103:539-547, 2000.
32. Enright PL, Burchette RJ, Peters JA, et al. Peak flow lability: Association with asthma and spirometry in an older cohort. Chest 112:895-901, 1997.
33. Halwani R, Al-Muhsen S, and Hamid Q. Airway remodeling in asthma. Curr Opin Pharmacol 10:236-245, 2010.
34. Dolan CM, Fraher KE, Bleecker ER, et al. Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and treatment regimens (TENOR) study: A large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 92:32-39, 2004.
35. Ulrik CS, and Backer V. Nonreversible airflow obstruction in life-long nonsmokers with moderate to severe asthma. Eur Respir J 14:892-896, 1999.
36. Rasmussen F, Taylor DR, Flannery EM, et al. Risk factors for airway remodeling in asthma manifested by a low postbron-chodilator FEV1/vital capacity ratio: A longitudinal population study from childhood to adulthood. Am J Respir Crit Care Med 165:1480-1488, 2002.
37. Vonk JM, Jongepier H, Panhuysen CI, et al. Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up. Thorax 58:322-327, 2003.
38. Ulrik CS. Outcome of asthma: Longitudinal changes in lung function. Eur Respir J 13:904-918, 1999.
39. Mirabelli MC, Beavers SF, and Chatterjee AB. Active asthma and the prevalence of physician-dianosed COPD. Lung 192: 693-700, 2014.
40. Lamprecht B, McBurnie MA, Vollmer WM, et al.; the BOLD Collaborative Research Group f. COPD in never smokers: Results From the Population-Based Burden of Obstructive Lung Disease study. Chest 139:752-763, 2011.
41. Silva GE, Sherrill DL, Guerra S, and Barbee RA. Asthma as a risk factor for COPD in a longitudinal study. Chest 126:59-65, 2004.
42. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD. 2013; Available online at www.goldcopd.org/; accessed August 28, 2014.
43. Fabbri LM, Romagnoli M, Corbetta L, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 167:418-424, 2003.
44. Available online at www.cdc.gov/asthma/asthmadata.htm; accessed August 28, 2014.
45. Available online at www.cdc.gov/copd/data.htm; accessed August 28, 2014.
46. Kitaguchi Y, Komatsu Y, Fujimoto K, et al. Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma. Int J Chron Obstruct Pulmon Dis 7:283-289, 2012.
47. Menezes AM, Montes de Oca M, Pérez-Padilla R, et al.; Platino team. Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPD. Asthma Chest 145:297-304, 2014.
48. Zeki AA, Schivo M, Chan A, et al. The asthma-COPD overlap syndrome: A common clinical problem in the elderly. J Allergy (Cairo) 2011:861926, 2011.
49. Soler-Cataluña JJ, Cosío B, Izquierdo JL, et al. Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol 48:331-337, 2012.
50. Louie S, Zeki AA, Schivo M, et al. The asthma-chronic obstructive pulmonary disease overlap syndrome: Pharmacotherapeutic considerations. Expert Rev Clin Pharmacol 6:197-219, 2013.
51. Hardin M, Silverman EK, Barr RG, et al.; COPDGene Investigators. The clinical features of the overlap between COPD and asthma. Respir Res 12:127, 2011.
52. Hardin M, Cho M, McDonald ML, et al. The clinical and genetic features of COPD-asthma overlap syndrome. Eur Respir J44: 341-350, 2014.
53. Piras B, and Miravitlles M. The overlap phenotype: The (missing) link between asthma and COPD. Multidiscip Respir Med 7:8, 2012.
54. Papi A, Romagnoli M, Baraldo S, et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 162:1773-1777, 2000.
55. Kunisaki KM, Rice KL, Janoff EN, et al. Exhaled nitric oxide, systemic inflammation, and the spirometric response to inhaled fluticasone propionate in severe chronic obstructive pulmonary disease: A prospective study. Ther Adv Respir Dis 2:55-64, 2008.
56. Foschino Barbaro MP, Carpagnano GE, Spanevello A, et al. Inflammation, oxidative stress and systemic effects in mild chronic obstructive pulmonary disease. Int J Immunopathol Pharmacol 20:753-763, 2007.
57. Contoli M, Baraldo S, Marku B, et al. Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: 5-Year follow-up. J Allergy Clin Immunol 125:830-837, 2010.
58. Perng DW, Huang HY, Chen HM, et al. Characteristics of airway inflammation and bronchodilator reversibility in COPD: A potential guide to treatment. Chest 126:375-381, 2004.
59. Papaiwannou A, Zarogoulidis P, Porpodis K, et al. Asthmachronic obstructive pulmonary disease overlap syndrome (ACOS): Current literature review. J Thorac Dis 6:S146-S151, 2014.
60. Hospers JJ, Schouten JP, Weiss ST, et al. Asthma attacks with eosinophilia predict mortality from chronic obstructive pulmonary disease in a general population sample. Am J Respir Crit Care Med 160:1869-1874, 1999.
61. Shaya FT, Dongyi D, Akazawa MO, et al. Burden of concomitant asthma and COPD in a Medicaid population. Chest 134: 14-19, 2008.
62. Iwamoto H, Gao J, Koskela J, et al. Differences in plasma and sputum biomarkers between COPD and COPD-asthma overlap. Eur Respir J 43:421-429, 2014.
63. Kitaguchi Y, Komatsu Y, Fujimoto K, et al. Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma. Int J Chron Obstruct Pulmon Dis 7:283-289, 2012.
64. Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 356: 1480-1485, 2000.
65. O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 Update. Can Respir J 14(suppl B):5B-32B, 2007.
66. Gibson PG, and Simpson JL. The overlap syndrome of asthma and COPD: What are its features and how important is it? Thorax 64:728-735, 2009.